

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission	232	Application Number	10/516,430
		Filing Date	11-30-2004
		First Named Inventor	Ralph Bohmer
		Art Unit	Not Yet Known
		Examiner Name	Not Yet Known
		Attorney Docket Number	311706

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Certificate of Mailing Under 37 CFR 1.8; Return Postcard
---	---	---


Remarks It is believed that no fees are due in this matter. However, if it is determined that fees are due, the Commissioner is authorized to debit Deposit Account No. 06-0029 for the required fees.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Faegre & Benson LLP		
Signature			
Printed Name	Richard A. Nakashima		
Date	8-15-2005	Reg. No.	42,023

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Terrie Quillin	Date	8-15-2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No.: 311706

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

on August 15, 2005

Date



Signature

Terrie Quillin

Typed or printed name of person signing Certificate

Registration Number if applicable

303-447-7741


Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal Form	1 page
Certificate of Mailing Under 37 CFR 1.8	1 page
Information Disclosure Statement	3 pages
Substitute for Form 1449A/PTO	2 pages
13 U.S. Patent References	copies not included
1 Foreign Patent Reference	104 pages
11 Other Art References	119 pages
Return Postcard	

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Ralph BOHMER

Serial No.: 10/516,430

Filed: November 30, 2004

Atty. Docket No.: 311706

For: MATERNAL ANTIBODIES AS
FETAL CELL MARKERS TO
IDENTIFY AND ENRICH FETAL
CELLS FROM MATERNAL BLOOD

) Group Art Unit: Not Yet Known

)

) Examiner: Not Yet Known

)

) INFORMATION DISCLOSURE

)

) STATEMENT

)

)

)

)

)

)

)

)

)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The references cited on attached Form PTO-1449 are being called to the attention of the Examiner.

☒ Copies of the cited non-patent and/or foreign references are enclosed herewith.

☐ Copies of the cited U.S. patents and/or patent application publications are enclosed herewith.

☒ Copies of the cited U.S. patents/patent application publications are not enclosed in accordance with the waivers dated July 11, 2003 and October 19, 2004, whereby patent applications filed, regardless of the filing date, need not submit copies of U.S. patents and U.S. patent application publications.

☐ Copies of the cited references are not enclosed, in accordance with 37 C.F.R. 1.98(d), because the references were cited by or submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____ filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

☐ To the best of applicants' belief, the pertinence of the foreign-language references are believed to be summarized in the attached English abstracts and in the figures, although applicants do not necessarily vouch for the accuracy of the translation.

☐ Examiner's attention is drawn to the following co-pending applications, copies of which have been or are being submitted:

Serial No. _____ filed

Serial No. _____ filed

☐ Other: _____

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

<input checked="" type="checkbox"/>	<p>37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith satisfies one of the following conditions ("X" indicates satisfaction):</p> <ul style="list-style-type: none"><input type="checkbox"/> Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or<input type="checkbox"/> Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or<input checked="" type="checkbox"/> Before the mailing date of a first Office Action on the merits, or<input type="checkbox"/> Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114. <p>Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.</p>
<input type="checkbox"/>	<p>37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions:</p> <ul style="list-style-type: none">(1) a final action under 37 C.F.R. 1.113 or(2) a notice of allowance under 37 C.F.R. 1.311, or(3) an action that otherwise closes prosecution in the application. <p>This Information Disclosure Statement is accompanied by:</p> <ul style="list-style-type: none"><input type="checkbox"/> A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. <p style="text-align: center;">OR</p> <ul style="list-style-type: none"><input type="checkbox"/> Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.

<input type="checkbox"/>	<p>37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c).</p> <p><input type="checkbox"/> This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e)</p> <p style="text-align: center;">AND</p> <p><input type="checkbox"/> Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.</p>
--------------------------	---


<p>Certification (37 C.F.R. 1.97(e)) (Applicable only if checked)</p>
<p><input type="checkbox"/> The undersigned certifies that:</p> <p style="margin-left: 40px;"><input type="checkbox"/> Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1).</p> <p style="margin-left: 80px;"><input type="checkbox"/> A copy of the communication from the foreign patent office is enclosed.</p> <p style="text-align: center;">OR</p> <p style="margin-left: 40px;"><input type="checkbox"/> No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).</p>

Respectfully submitted,

FAEGRE & BENSON LLP

CUSTOMER NO.: 35657

Date: August 15, 2005

By: 
 Richard A. Nakashima, Esq.
 Atty. Reg. No.: 42,023
 Telephone: (303) 447-7728



Substitute for form 1449A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/516,430
Filing Date	November 30, 2004
First Named Inventor	Ralph Bohmer
Art Unit	
Examiner Name	
Attorney Docket Number	311706

Sheet 1 of 2

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-3,817,837	06/18/1974	Rubenstein et al.	
	2	US-3,850,752	11/26/1974	Schuurs et al.	
	3	US-3,939,350	02/17/1976	Kronick et al.	
	4	US-3,996,345	12/07/1976	Ullman et al.	
	5	US-4,366,241	12/28/1982	Tom et al.	
	6	US-4,275,149	06/23/1981	Litman et al.	
	7	US-4,277,437	07/07/1981	Maggio	
	8	US-5,641,870	06/24/1997	Rinderknecht et al.	
	9	US-5,798,276	08/25/1998	Haugland et al.	
	10	US-5,830,912	11/03/1998	Gee et al.	
	11	US-5,969,157	10/19/1999	Vicenzi	
	12	US-6,130,101	10/10/2000	Mao et al.	
	13	US-6,162,931	12/19/2000	Gee et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	14	PCT - WO 02/26891 A1	04/04/2002	Molecular Probes Inc.		
		-				
		-				
		-				
		-				
		-				
		-				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/516,430
Filing Date	November 30, 2004
First Named Inventor	Ralph Bohmer
Art Unit	
Examiner Name	
Attorney Docket Number	311706

Sheet 2 of 2

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. ¹	
	15	BIANCHI; "Fetal Cells in the Mother: From Genetic Diagnosis to Diseases Associated With Fetal Cell Microchimerism"; 2000; European Journal of Obstetrics & Gynecology and Reproductive Biology; 92; pp. 103-108
	16	COPPOLA et al.; "High-Performance Liquid Chromatography of Amino Acids, Peptides and Proteins: XCIII ^a . Comparison of Methods for the Purification of Mouse Monoclonal Immunoglobulin M Autoantibodies"; 1989; Journal of Chromatography; 476; pp. 269-290
	17	NEVENS et al.; "Affinity Chromatographic Purification of Immunoglobulin M Antibodies Utilizing Immobilized Mannan Binding Protein"; 1992; Journal of Chromatography; 597; pp. 247-256
	18	AL-MUFTI et al.; "Investigation of Maternal Blood Enriched for Fetal Cells: Role in Screening and Diagnosis of Fetal Trisomies"; 1999; American Journal of Medical Genetics; 85; pp. 66-75
	19	DOUGLAS et al.; "Trophoblast in the Circulating Blood During Pregnancy"; Nov. 1959; American Journal of Obstetrics & Gynecology; V. 78; No. 5; pp. 960-973
	20	FOLKERSEN et al.; "An Immunoprecipitation-Dissociation Technique for Large Scale Antibody Purification and an Antigen Consumption Electroimmunoassay for Antibody Quantitation. A Model Study with Antibodies to Pregnancy Zone Protein"; 1978; Journal of Immunological Methods; 23; pp. 127-135
	21	HOFFMANN et al.; "Continuous Free-Flow Electrophoresis Separation of Cytosolic Proteins from the Human Colon Carcinoma Cell Line LIM 1215: A Non Two-Dimensional Gel Electrophoresis-Based Proteome Analysis Strategy"; 2001; Proteomics; 1; pp. 807-818
	22	PARKER et al.; "Biophysical Characteristics of Anti-Gal α 1-3Gal IgM Binding to Cell Surfaces: Implications for Xenotransplantation"; 2-15-2001; Transplantation; V. 71; pp. 440-446, No. 3
	23	SCHRÖDER; "Transplacental Passage of Blood Cells"; 1975; Journal of Medical Genetics; 12; pp. 230-242
	24	SISSON et al.; "An Improved Method for Immobilizing IgG Antibodies on Protein A-agarose"; 1990; Journal of Immunological Methods; 127; pp. 215-220
	25	TSANG et al.; "Optimum Dissociating Condition for Immunoaffinity and Preferential Isolation of Antibodies with High-Specific Activity"; 1991; Journal of Immunological Methods; 138; pp. 291-299

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.